List of Excipients in Branded Drug OSELTAMIVIR PHOSPHATE

Generic Drugs Containing OSELTAMIVIR PHOSPHATE

Company	Ingredient	NDC	Excipient
Teva Pharmaceuticals USA Inc	oseltamivir phosphate	0093-8180	.ALPHA.-TOCOPHEROL, DL-
Teva Pharmaceuticals USA Inc	oseltamivir phosphate	0093-8180	BENZYL ALCOHOL
Teva Pharmaceuticals USA Inc	oseltamivir phosphate	0093-8180	MALTODEXTRIN

What are the Most Frequently-Used Excipients in OSELTAMIVIR PHOSPHATE?

# Of NDCs	Excipient
3	.ALPHA.-TOCOPHEROL, DL-
9	ALCOHOL
16	AMMONIA

Oseltamivir Phosphate Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: August 7, 2026

Oseltamivir phosphate is a mature, globally supplied influenza antiviral with limited composition-of-matter protection and substantial generic competition. Commercial opportunity has shifted from basic capsule replication to formulation differentiation, pediatric usability, stockpile logistics, supply assurance, and region-specific regulatory execution. The most attractive excipient strategies reduce hydrolysis risk, improve powder reconstitution, mask bitterness, support low-dose pediatric administration, and extend stability under government-stockpile conditions.

What is the commercial status of oseltamivir phosphate?

Oseltamivir phosphate is the oral prodrug of oseltamivir carboxylate, a neuraminidase inhibitor used for treatment and prophylaxis of influenza A and B. Roche markets the originator product as Tamiflu. The FDA-approved dosage forms are hard capsules and an oral suspension powder that is reconstituted before administration. FDA-approved capsule strengths are 30 mg, 45 mg, and 75 mg of oseltamivir, expressed as the active moiety. The commercial suspension is commonly supplied at 6 mg/mL after reconstitution.[1]

The market is mature and genericized. Competition is based on:

• Unit cost and manufacturing reliability
• Government procurement qualification
• Pediatric dosing and palatability
• Shelf life and packaging
• Supply continuity during influenza surges
• Geographic registration and local manufacturing
• Differentiated delivery systems

Oseltamivir phosphate does not have the commercial profile of a protected specialty drug. Its value is tied to seasonal demand, public-health stockpiles, pandemic preparedness and short treatment courses.

Key commercial facts

Item	Position
Active ingredient	Oseltamivir phosphate
Active metabolite	Oseltamivir carboxylate
Originator	Roche, marketed as Tamiflu
Original discovery and development relationship	Gilead Sciences discovered oseltamivir; Roche obtained development and commercialization rights
Therapeutic class	Oral neuraminidase inhibitor
Principal dosage forms	Capsules and reconstituted oral suspension
Common adult treatment regimen	75 mg twice daily for five days
Pediatric and prophylaxis use	Weight- and age-dependent dosing
Regulatory pathway	Small-molecule NDA and abbreviated new drug applications
Biosimilar exposure	None
Current competitive model	Generic and authorized-generic supply, government tenders, branded supply

The Tamiflu-Gilead relationship originated in the 1990s. Gilead disclosed that Roche held commercialization rights and that Gilead received royalties related to Tamiflu sales.[2] The royalty structure and current commercial terms are not generally disclosed in product labeling.

What excipients are used in oseltamivir phosphate capsules and suspension?

The reference capsule formulation uses conventional immediate-release excipients. The reference suspension uses a different strategy because it must produce a stable powder, reconstitute rapidly, remain physically uniform, and provide acceptable taste for children.

Reference capsule excipient system

The Tamiflu capsule formulation has used a combination of:

• Pregelatinized starch as a filler and binder
• Povidone K30 as a binder
• Croscarmellose sodium as a disintegrant
• Talc as a processing aid
• Sodium stearyl fumarate as a lubricant
• Gelatin capsule shell materials
• Colorants and titanium dioxide, depending on strength and shell design

The capsule strategy is operationally conservative. It supports conventional high-speed encapsulation and rapid disintegration without requiring a specialized release mechanism.[1]

Reference oral suspension excipient system

The reconstituted suspension has used excipients that address taste, microbial protection, pH control and physical stability. The reference formulation includes:

• Sorbitol for bulk and sweetness
• Sodium citrate or citrate buffering components
• Sodium benzoate as a preservative
• Saccharin sodium as an intense sweetener
• Titanium dioxide as an opacifier
• Flavoring components

Generic products may use different quantitative compositions or alternative excipients while maintaining the same labeled strength, performance and safety profile.

Excipient functions by dosage form

Formulation objective	Capsule approach	Suspension approach
Dose uniformity	Blend uniformity and capsule fill control	Assay after reconstitution and suspension uniformity
Disintegration	Croscarmellose sodium and porous blend	Rapid wetting and dispersion
Taste	Not usually relevant after swallowing	Sweetener, flavor and bitterness masking
Stability	Moisture-controlled packaging	Dry powder until use, preservative after reconstitution
Manufacturing	Direct blending or granulation followed by encapsulation	Powder blending, filling and reconstitution validation
Pediatric use	Limited suitability for young children	Primary pediatric dosage form
Supply-chain risk	Capsule shell and API moisture control	Bottle, closure, measuring device, flavor and preservative supply

How should excipient selection address oseltamivir phosphate stability?

The principal formulation risk is maintaining assay and impurity control through manufacture, storage, reconstitution and use. A dry capsule or dry suspension intermediate generally offers a stronger stability profile than a ready-to-use aqueous liquid.

Moisture management

A moisture-control program should evaluate:

• Water activity of the final blend
• API and excipient hygroscopicity
• Moisture ingress through the bottle or blister
• Capsule-shell moisture transfer
• Reconstituted suspension stability
• Hydrolytic degradation and impurity formation

High-barrier blister films, induction-sealed bottles and desiccant-equipped secondary packaging can reduce water exposure. Desiccants are more relevant for capsules and dry powders than for the reconstituted product.

Lubricant selection

Sodium stearyl fumarate is useful where the developer wants lower hydrophobicity than conventional magnesium stearate. Magnesium stearate remains commercially attractive because of cost and supply, but its concentration and blending time require control to avoid delayed disintegration or content-uniformity effects.

For generic development, lubricant selection can become a practical differentiator when the API has poor flow, the blend is low-dose, or the product must meet short disintegration targets.

Binder and disintegrant strategy

Povidone, copovidone, pregelatinized starch and low-substituted hydroxypropyl cellulose can support granulation or direct-compression designs. Croscarmellose sodium, crospovidone and sodium starch glycolate provide alternative disintegration systems.

A robust development sequence should compare:

1. Direct blend and encapsulation
2. Dry granulation for flow improvement
3. Wet granulation where segregation or compressibility is limiting
4. Capsule-in-capsule or multiparticulate designs for pediatric delivery
5. Dispersible or orally disintegrating formats

The commercial target is not maximum excipient complexity. It is a reproducible product that meets dissolution, assay, impurity and stability requirements at low cost.

What formulation patents protect oseltamivir products?

The core oseltamivir compound patent estate has expired in major markets. Commercial protection is therefore more likely to arise from formulation, dosage, process, packaging or manufacturing claims than from the active ingredient itself.

Potential patent categories include:

• Specific suspension compositions
• Taste-masked oral formulations
• Pediatric dosage forms
• Orally disintegrating tablets
• Granules, powders or sachets
• Combination products
• Improved manufacturing processes
• Stable solid forms or particle-size controls
• Container-closure systems
• Dosing devices
• Pandemic-stockpile formulations

A formulation patent must be assessed claim by claim. A broad claim to an ordinary capsule containing oseltamivir phosphate is unlikely to provide meaningful protection in a mature market. A narrower claim covering a defined excipient ratio, stability threshold, reconstitution performance or taste-masking system may still support an abbreviated product strategy if it is valid, enforceable and commercially relevant.

Orange Book status and listed patents

FDA Orange Book review is the relevant U.S. screening tool for patents and regulatory exclusivity associated with approved drug products.[3] The originator’s basic small-molecule exclusivity has expired, and oseltamivir is supplied through generic ANDA pathways. Any current patent analysis must distinguish:

• Patents listed for the reference product
• Unlisted formulation or process patents
• Expired patents
• Pediatric exclusivity
• Regulatory exclusivity
• Patents owned by third parties
• Patents covering a specific generic manufacturer’s formulation

A patent that is not listed in the Orange Book may still affect manufacturing or commercialization, but it does not automatically create the same ANDA certification consequences as an Orange Book-listed patent.

When does oseltamivir lose exclusivity?

Oseltamivir’s practical market exclusivity ended after expiration of the principal composition-of-matter and product protection period. Generic oseltamivir products have been approved in the United States and other major markets for years.

Exclusivity category	Commercial position
Composition-of-matter protection	Expired in major markets
Original product exclusivity	Expired
Pediatric exclusivity	Historical, expired
Current biosimilar exclusivity	Not applicable
Current generic competition	Established
Formulation-specific protection	Must be reviewed by product and jurisdiction
Government procurement advantage	Depends on supply qualification, not patent exclusivity

The relevant competitive question is no longer whether a generic can enter the active ingredient market. It is whether a new entrant can obtain approval, manufacture at scale, qualify for tenders and maintain supply during demand spikes.

Which companies are challenging or competing with Tamiflu?

The competitive set includes generic manufacturers, regional pharmaceutical companies and alternative influenza antivirals.

Oseltamivir competitors

Generic manufacturers have competed through capsules and oral suspension products. The identity of active suppliers differs by jurisdiction and changes through procurement cycles. In the United States, FDA-approved generic oseltamivir products are the principal direct competitors to Tamiflu.

Therapeutic competitors

Product	Active ingredient	Dosage form	Competitive distinction
Tamiflu and generics	Oseltamivir phosphate	Capsules, suspension	Oral, established stockpile product
Relenza	Zanamivir	Inhaled powder	Inhaled administration
Rapivab	Peramivir	Intravenous	Hospital and severe-case use
Xofluza	Baloxavir marboxil	Oral tablet or granules in selected markets	Single-dose treatment in eligible patients

Baloxavir competes on single-dose convenience, while oseltamivir benefits from broad familiarity, established pediatric use and stockpile infrastructure. Zanamivir and peramivir have administration limitations that can favor oral oseltamivir in outpatient and public-health settings.[4]

What excipient-based commercial opportunities exist for oseltamivir phosphate?

The strongest opportunities are formulation-led rather than patent-led.

Pediatric taste-masked suspension

Pediatric suspension is the clearest opportunity. Product developers can compete through:

• Improved bitterness masking
• Lower sugar or sugar-free systems
• Reduced preservative burden
• Better flavor persistence
• Smaller reconstitution volume
• Oral syringes with dose markings
• Longer in-use stability
• Less sedimentation and easier redispersion

A taste-masking system may combine polymeric coating, ion-exchange technology, cyclodextrin complexation, lipid-based barriers or optimized sweetener-flavor systems. Each approach must preserve release and bioavailability.

Ready-to-use and unit-dose liquids

A ready-to-use suspension eliminates reconstitution errors but increases microbial, chemical and shipping risks. Unit-dose sachets or premeasured powders can improve stockpile deployment, reduce dosing errors and simplify pharmacy operations.

The trade-off is packaging cost. A dry powder in a lightweight bottle generally has better long-term logistics than an aqueous product.

Orally disintegrating and dispersible products

Orally disintegrating tablets and dispersible tablets could support patients who cannot swallow capsules. The formulation must control:

• Tablet friability
• Mouthfeel
• Bitterness
• Moisture sensitivity
• Dose loading
• Disintegration time
• Packaging barrier performance

These products are most commercially relevant for pediatric, geriatric and field-use segments.

Low-cost stockpile formulations

Public-health buyers value products with:

• Long shelf life
• Simple storage conditions
• High packaging density
• Low reconstitution error
• Stable supply of critical excipients
• Multiple qualified manufacturing sites

A manufacturer may gain a procurement advantage by qualifying alternative excipient suppliers and maintaining validated dual sourcing for sweeteners, preservatives, capsule shells, flavors and packaging components.

What manufacturing and intellectual-property barriers affect oseltamivir?

The active ingredient is no longer the principal barrier. Manufacturing execution is more important.

API and process controls

Key controls include:

• Assay and related substances
• Residual solvents
• Particle-size distribution
• Polymorphic or solid-state consistency
• Blend segregation
• Encapsulation weight variation
• Moisture exposure
• Reconstitution performance

Oseltamivir phosphate manufacturing also requires control of stereochemistry and process impurities. A low-cost API source that produces variable particle size or impurity profiles can increase formulation and regulatory risk.

Excipient supply risks

Seasonal demand can create bottlenecks in:

• Pharmaceutical-grade sorbitol
• Flavor systems
• Sodium benzoate
• Capsule shells
• High-barrier bottles
• Oral syringes
• Specialty coating polymers

A formulation dependent on one proprietary flavor or one regional excipient supplier may be less competitive in government tenders than a formulation designed around broadly available materials.

What is the Paragraph IV and litigation risk for oseltamivir?

Because the main oseltamivir exclusivity period has expired, the historical Paragraph IV risk has largely transitioned into ordinary product and process risk. A new ANDA sponsor would still assess:

• Current Orange Book listings
• Any pending patent litigation
• Unlisted process patents
• Formulation patents
• Device or dosing-system rights
• Supplier indemnities
• Regulatory exclusivity tied to a specific indication or dosage form

A Paragraph IV certification can trigger litigation under the Hatch-Waxman framework when an applicable listed patent remains in force. In a mature oseltamivir market, the more material litigation exposure is likely to concern a differentiated suspension, delivery system or manufacturing process rather than the basic active ingredient.

No biosimilar litigation pathway applies because oseltamivir is a synthetic small molecule, not a biologic.

How strong is the oseltamivir phosphate patent estate?

The estate is weak for basic generic entry and potentially stronger for narrow formulation innovation.

Patent category	Relative strength
Basic active ingredient	Low, expired
Standard immediate-release capsule	Low
Conventional suspension	Low to moderate, depending on claim scope
Taste-masking technology	Moderate if technically specific
Pediatric delivery system	Moderate
Novel manufacturing process	Moderate if difficult to design around
Packaging and stockpile system	Low to moderate
Combination therapy	Product- and claim-specific

Patent value depends on claim breadth, remaining term, freedom-to-operate coverage, enablement, obviousness risk and the ability to detect infringement. A formulation patent with narrow excipient percentages may be easy to design around unless it captures a measurable performance result.

What are the generic launch scenarios for oseltamivir?

Scenario 1: Standard capsule launch

This is the lowest-risk strategy. The product competes on price, supply reliability and regulatory execution. Margin pressure is high, and differentiation is limited.

Scenario 2: Pediatric suspension launch

This offers greater commercial differentiation. The developer can compete on taste, reconstitution, in-use stability and dosing accessories. Regulatory development is more demanding than for a standard capsule.

Scenario 3: Dispersible or orally disintegrating product

This targets swallowing difficulty and field deployment. It may command a modest premium if the product solves a meaningful administration problem.

Scenario 4: Stockpile-focused product

A manufacturer can seek government contracts using long shelf life, dual-source manufacturing, high-density packaging and pandemic-readiness capacity. Volume may be irregular, but contracts can support baseline production.

Scenario 5: Regional licensing or contract manufacturing

A formulation owner can license a pediatric or differentiated dosage form to regional manufacturers. Local partners may provide tender access, registration infrastructure and manufacturing capacity.

How does oseltamivir compare with competing influenza antivirals?

Oseltamivir remains commercially attractive because it combines oral administration, broad clinical familiarity, established pediatric dosing and procurement history. Its disadvantages are the twice-daily five-day regimen, gastrointestinal adverse effects in some patients and heavy generic price competition.

Baloxavir has a dosing-convenience advantage, but its formulation, labeling and resistance considerations differ. Zanamivir has inhalation requirements. Peramivir requires intravenous administration. These differences leave room for oseltamivir products that improve usability without changing the active ingredient.

What is the revenue exposure for oseltamivir phosphate?

Roche does not generally report Tamiflu as a separately detailed current revenue line in the way it reports major growth products. Revenue is seasonal, influenced by influenza incidence, government stockpiling, public-health orders and competitive generic pricing.

For a generic manufacturer, revenue concentration can be high because:

• Influenza demand is seasonal
• Tender awards can be lumpy
• Government purchasing is price-sensitive
• Stockpile contracts may use minimum-volume commitments
• Demand can rise sharply during outbreaks and fall rapidly afterward

The best commercial model combines baseline pharmacy sales with government procurement and geographically diversified registration.

Key Takeaways

• Oseltamivir phosphate is a mature, genericized oral influenza antiviral.
• Core compound and original product exclusivity have expired in major markets.
• No biosimilar pathway applies.
• Standard capsules offer limited formulation differentiation.
• Pediatric suspension is the strongest excipient-led opportunity.
• Taste masking, low-sugar systems, reconstitution performance and dosing devices can create commercial value.
• Moisture control is central to capsule and dry-powder stability.
• Stockpile buyers prioritize shelf life, packaging density, supply continuity and dual sourcing.
• The principal legal risks now relate to narrow formulation, process, device and packaging patents.
• Generic profitability depends more on procurement access and manufacturing reliability than on active-ingredient patent protection.

FAQs About Oseltamivir Phosphate Formulation and Commercialization

Can oseltamivir phosphate be formulated as an orally disintegrating tablet?

Yes. An orally disintegrating or dispersible formulation is technically feasible, but development must address bitterness, moisture sensitivity, dose loading, tablet strength and dissolution.

Which excipient is most important for oseltamivir suspension taste masking?

No single excipient is determinative. A combined system using sweeteners, flavors, buffering agents and a physical or chemical taste-masking technology is more likely to provide acceptable pediatric performance.

Is a sugar-free oseltamivir suspension commercially viable?

Yes. A sugar-free suspension could target diabetic patients, pediatric products with reduced sugar exposure and institutional buyers. The developer must validate viscosity, palatability, preservative effectiveness and microbial stability.

Can oseltamivir phosphate be sold without a patent license?

In markets where relevant composition, formulation and process patents have expired or do not apply, a manufacturer can generally pursue independent regulatory approval without an originator license. Freedom-to-operate analysis remains product- and jurisdiction-specific.

What is the highest-value oseltamivir product opportunity?

A stable, palatable pediatric product with simplified dosing, robust packaging and long in-use stability is likely to offer more differentiation than another conventional 75 mg capsule.

References

1. U.S. Food and Drug Administration. (2024). Tamiflu (oseltamivir phosphate) prescribing information.
2. Gilead Sciences, Inc. (1997-2024). Annual reports and filings describing oseltamivir phosphate and Roche licensing arrangements.
3. U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations: Orange Book.
4. Centers for Disease Control and Prevention. (2024). Influenza antiviral medications: Summary for clinicians.